Bicycle Therapeutics was founded in 2009 based on innovative science conducted in the laboratory of the globally respected Professor Sir Greg Winter, a pioneer in monoclonal antibodies, to translate first-in-class Bicycles into transformative medicines for life-altering diseases.
The venture has become a transatlantic company, with headquarters in Cambridge UK and many key functions and members of the leadership team located in the biotech hub of Boston, Mass.
Its proprietary bicyclic peptide (Bicycle®) product platform has captured attention from Big Pharma and cancer practitioners alike.
In May 2018, Bicycle Therapeutics expanded its collaboration with AstraZeneca to include additional targets in respiratory and cardio-metabolic diseases.
The original collaboration was signed in late 2016 and with the expansion has a potential value in excess of $1 billion. Under the terms of the collaboration Bicycle is responsible for identifying Bicycles® for an undisclosed number of respiratory, cardiovascular and metabolic disease targets specified by AstraZeneca, while AstraZeneca is responsible for further development and product commercialisation.